Literature DB >> 18789568

Visual pathway deficit in female fragile X premutation carriers: a potential endophenotype.

Szabolcs Kéri1, György Benedek.   

Abstract

Previous studies indicated impaired magnocellular (M) and relatively spared parvocellular (P) visual pathway functioning in patients with fragile X syndrome. In this study, we assessed M and P pathways in 22 female fragile X premutation carriers with normal intelligence and in 20 healthy non-carrier controls. Testing procedure included visual contrast sensitivity and vernier threshold measurements. Results revealed that carriers were selectively impaired on tests of M pathways (low spatial/high temporal frequency contrast sensitivity and frequency-doubling vernier), whereas they showed intact performance on P pathway tests. These results suggest that the deficit of the M pathway is an endophenotype of fragile X syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789568     DOI: 10.1016/j.bandc.2008.08.002

Source DB:  PubMed          Journal:  Brain Cogn        ISSN: 0278-2626            Impact factor:   2.310


  21 in total

Review 1.  Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders.

Authors:  Michael R Hunsaker
Journal:  Prog Neurobiol       Date:  2012-01-13       Impact factor: 11.685

2.  Motor deficits on a ladder rung task in male and female adolescent and adult CGG knock-in mice.

Authors:  Michael R Hunsaker; Ramona E von Leden; Binh T Ta; Naomi J Goodrich-Hunsaker; Gloria Arque; Kyoungmi Kim; Rob Willemsen; Robert F Berman
Journal:  Behav Brain Res       Date:  2011-03-31       Impact factor: 3.332

3.  Female CGG knock-in mice modeling the fragile X premutation are impaired on a skilled forelimb reaching task.

Authors:  Amanda A Diep; Michael R Hunsaker; Richard Kwock; Kyoungmi Kim; Rob Willemsen; Robert F Berman
Journal:  Neurobiol Learn Mem       Date:  2011-12-21       Impact factor: 2.877

4.  CGG trinucleotide repeat length modulates neural plasticity and spatiotemporal processing in a mouse model of the fragile X premutation.

Authors:  Michael R Hunsaker; Kyoungmi Kim; Rob Willemsen; Robert F Berman
Journal:  Hippocampus       Date:  2012-06-18       Impact factor: 3.899

5.  Altered neural activity in the 'when' pathway during temporal processing in fragile X premutation carriers.

Authors:  So-Yeon Kim; Flora Tassone; Tony J Simon; Susan M Rivera
Journal:  Behav Brain Res       Date:  2014-01-05       Impact factor: 3.332

6.  Intense and specialized dendritic localization of the fragile X mental retardation protein in binaural brainstem neurons: a comparative study in the alligator, chicken, gerbil, and human.

Authors:  Yuan Wang; Hitomi Sakano; Karisa Beebe; Maile R Brown; Rian de Laat; Mark Bothwell; Randy J Kulesza; Edwin W Rubel
Journal:  J Comp Neurol       Date:  2014-06-15       Impact factor: 3.215

7.  Young adult female fragile X premutation carriers show age- and genetically-modulated cognitive impairments.

Authors:  Naomi J Goodrich-Hunsaker; Ling M Wong; Yingratana McLennan; Siddharth Srivastava; Flora Tassone; Danielle Harvey; Susan M Rivera; Tony J Simon
Journal:  Brain Cogn       Date:  2011-02-03       Impact factor: 2.310

8.  Using perceptual signatures to define and dissociate condition-specific neural etiology: autism and fragile X syndrome as model conditions.

Authors:  Armando Bertone; Julie Hanck; Cary Kogan; Avi Chaudhuri; Kim Cornish
Journal:  J Autism Dev Disord       Date:  2010-12

9.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

10.  Altered neural activity of magnitude estimation processing in adults with the fragile X premutation.

Authors:  So-Yeon Kim; Ryu-ichiro Hashimoto; Flora Tassone; Tony J Simon; Susan M Rivera
Journal:  J Psychiatr Res       Date:  2013-09-02       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.